The U.S. Food and Drug Administration (FDA) on Monday lifted the clinical hold on GH Research Plc’s (NASDAQ:GHRS) Investigational New Drug Application (IND) for GH001.GH Research stock is showing positive momentum. What’s ahead for GHRS stock?“The FDA clearance is a major milestone and positions us to advance GH001 as a potential ultra-rapid and durable treatment option for TRD patients,” said Dr. Velichka Valcheva, Chief Executive Officer. “We continue to expect initiation of our global pivotal program in ...